Studies demonstrate that the investigational 64Cu-DOTATATE radiopharmaceutical may
provide diagnostic and logistical benefits over available imaging agents for patients with …

Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up, and treatment
planning of neuroendocrine tumor (NET). PET-based tracers using 68Ga as the radioisotope …

Neuroendocrine tumors (NETs) can be visualized using radiolabeled somatostatin analogs.
We have previously shown the clinical potential of 64Cu-DOTATATE in a small first-in …

Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and
therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of …

Imaging of somatostatin receptor expression is an established technique for staging of
neuroendocrine neoplasia and determining the suitability of patients for peptide receptor …

Overexpression of somatostatin receptors (SSTRs) in patients with neuroendocrine
neoplasms (NENs) is used for both diagnosis and treatment. Receptor density may reflect …

Somatostatin receptor (SSTR) imaging using PET has replaced scintigraphic imaging using
111In-pentetreotide (OctreoScan), unless PET is unavailable. Several benefits of SSTR PET …

PET-CT with somatostatin analogs labeled with 68 Ga is increasingly recognized as the best
imaging modality for the evaluation of well-differentiated neuroendocrine tumors (NETs) …

68Ga-DOTATATE PET/CT provides information on the location of somatostatin receptor–
expressing tumors. Integrating this imaging data effectively in patient care requires the …

Somatostatin receptor (SSTR) imaging has brought about impactful changes in clinical
management of neuroendocrine tumors (NETs), including pheochromocytoma and …